- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
Frontage Holdings
Market Cap: HK$2.5b
Provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.22
7D
-3.6%
1Y
-17.3%
Innovent Biologics
Market Cap: HK$173.2b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$100.10
7D
3.6%
1Y
4.5%
InSilico Medicine Cayman TopCo
Market Cap: HK$23.1b
Engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
3696
HK$46.30
7D
11.6%
1Y
n/a
CanSino Biologics
Market Cap: HK$13.6b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$28.32
7D
17.1%
1Y
-43.4%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$55.6b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$62.05
7D
-1.8%
1Y
178.5%